Abstract
The effect of verapamil on plasma lipids and lipoproteins was studied in 64 patients taking part in a double blind controlled trial of verapamil versus placebo in post myocardial infarction. During a six month treatment period no significant difference was seen in plasma cholesterol, triglycerides, high density lipoproteins or low density lipoproteins.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Cholesterol / blood
-
Female
-
Humans
-
Lipoproteins / blood*
-
Lipoproteins, HDL / blood
-
Lipoproteins, LDL / blood
-
Male
-
Middle Aged
-
Myocardial Infarction / blood*
-
Myocardial Infarction / drug therapy
-
Placebos
-
Triglycerides / blood
-
Verapamil / pharmacology*
-
Verapamil / therapeutic use
Substances
-
Lipoproteins
-
Lipoproteins, HDL
-
Lipoproteins, LDL
-
Placebos
-
Triglycerides
-
Cholesterol
-
Verapamil